Press Release

HeartFlow Announces Completion of Patient Enrollment in the PRECISE Trial

2,100 patients enrolled in randomized controlled trial to evaluate a precision-testing pathway for suspected coronary artery disease

REDWOOD CITY, Calif. – May 11, 2021 — HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced the completion of patient enrollment in the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) randomized controlled trial. Physicians from more than 50 hospitals around the world successfully enrolled 2,100 patients.

“With the PRECISE trial, we aim to demonstrate that a coronary-CTA led diagnostic pathway tailored to patient risk will offer greater precision in the diagnosis and management of patients with suspected CAD, while reducing the number, risks, and costs of unnecessary tests and procedures,” said Pamela Douglas, M.D., MACC, FASE, FAHA, the Ursula Geller Professor for Research in Cardiovascular Disease, Duke University School of Medicine and study chair of the PRECISE trial. “The pace of enrollment in the PRECISE trial was outstanding, despite the global pandemic, reinforcing that coronary artery disease remains one of the most important health issues we face as a society.”

The PRECISE trial is designed to compare a “Usual Care” approach of diagnosing and evaluating patients with stable chest pain using a stress test and/or invasive cardiac catheterization to a new “Precision Evaluation Strategy” using risk-based testing and coronary computed tomography angiography (CTA) scans coupled with the HeartFlow FFRCT Analysis, when indicated. The PRECISE trial will evaluate whether the new “Precision Evaluation Strategy” can improve the accuracy, outcomes, efficiency, and cost of diagnosing and caring for patients with suspected coronary artery disease (CAD).

Patients enrolled in the PRECISE trial were randomized to either the “Usual Care” or “Precision Evaluation Strategy” arm. Patients in the “Precision Evaluation Strategy” arm were assessed using the PROMISE Minimal Risk Score and placed in either a low/no risk group or the intermediate/high risk group. Patients in the low/no risk group were treated with medications and lifestyle modifications but no immediate planned testing. Patients in the intermediate/high risk group underwent a coronary CTA, and when additional information was needed, a HeartFlow FFRCT Analysis was conducted. The primary endpoint of the PRECISE trial is the rate of major adverse cardiac events comprised of death, heart attack (myocardial infarction) or invasive coronary angiography without obstructive disease at 1 year.

“We want to thank all of the patients, physicians, and research teams participating in the PRECISE trial for sharing our vision of advancing the scientific evidence for improving the diagnostic pathway for patients with CAD,” said Campbell Rogers, MD, FACC, Chief Medical Officer, HeartFlow. “HeartFlow is committed to providing the highest quality and most clinically relevant data to providers and patients, and we look forward to the results from the PRECISE trial being presented in the future.”

ENDS

About the HeartFlow FFRCT Analysis

Starting with a standard coronary CTA, the HeartFlow Analysis leverages deep learning and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRCT values along the coronary arteries. This information helps physicians evaluate the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. A positive FFRCT value (≤0.80) indicates that a coronary blockage is impeding blood flow to the heart muscle to a degree which may warrant invasive management.

Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow Analysis have been published in more than 425 peer-reviewed publications, including long-term data out to five years. The HeartFlow Analysis offers the highest diagnostic performance available from a non-invasive test.1 To date, clinicians around the world have used the HeartFlow Analysis for more than 75,000 patients to aid in the diagnosis of heart disease.

About HeartFlow, Inc.

HeartFlow, Inc. is a leader in revolutionizing precision heartcare, uniquely combining human ingenuity with advanced technology. Our non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized 3D model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. Our technology is reflective of our Silicon Valley roots and incorporates decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, Canada, Europe and Japan. For more information, visit www.heartflow.com.

###

  1. Driessen, R., et al. Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis. J Am Coll Cardiol. 2019;73(2),161-73.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.